Bank of America
SUPN icon

Bank of America’s Supernus Pharmaceuticals SUPN Stock Holding History

Bank of America’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-21,100
Closed -$440K – 7357
2020
Q3 		$440K Buy
+21,100
New +$479K ﹤0.01% 4807
2014
Q2 		– Sell
-250,000
Closed -$2.23M – 8195
2014
Q1 		$2.23M Buy
+250,000
New +$2.3M ﹤0.01% 3124

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America's SUPN Position: Q1 2026 in Review

Bank of America increased its Supernus Pharmaceuticals (SUPN) stake by 37% in Q1 2026, buying an estimated $9.85M and bringing the position to 714,226 shares worth $36.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1850.

Bank of America first reported a position in SUPN in Q2 2013 and has held it in 52 quarters since. The position peaked at $40.3M in Q3 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Bank of America held 714,226 shares of Supernus Pharmaceuticals worth $36.9M as of Q1 2026.
  • Bank of America bought 193,479 Supernus Pharmaceuticals shares in Q1 2026, an estimated $9.85M.
  • Supernus Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #1850 holding.
  • Bank of America first reported a position in Supernus Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Bank of America's Supernus Pharmaceuticals position peaked at $40.3M in Q3 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.